Richard Feifer
CIK 1814811 · View on SEC EDGAR ↗
First SEC filing: Aug. 17, 2023 · Latest: Aug. 17, 2023
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Aug. 15, 2023 | INNV | F | 9,737 | $5.60 | $54,527 | 135,008 Direct | -6.73% | Disposed | 92.1% (price as of 2026-08-20) |
| June 6, 2023 | INNV | A | 52,152 | — | — | 144,745 Direct | +56.32% | Acquired | (price as of 2026-08-20) |
| Aug. 15, 2022 | INNV | A | 92,593 | — | — | 92,593 Direct | — | Acquired | (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
INNV
Chief Medical Officer(6)| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $351,667 | — | $800,008 | — | $183,014 | — | $4,000 | $1,338,689 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.